Relypsa up in debut, but off highs


Relypsa (RLYP +8.5%) opens at $12.47, or around 13% above where the IPO priced.

The company is developing patiromer for the treatment of hyperkalemia.

Earlier this month, RLYP reported more data to support significant top-line efficacy results from a two-part clinical trial.

The company notes that it has "global royalty-free commercialization rights to patiromer, which has intellectual property protection in the U.S. until at least 2030."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs